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Abstract
Heart	failure	with	preserved	ejection	fraction	(HFpEF)	is	the	most	common	type	of	
HF	in	older	adults.	Although	no	pharmacological	therapy	has	yet	improved	survival	
in	HFpEF,	exercise	training	(ExT)	has	emerged	as	the	most	effective	intervention	to	
improving	 functional	 outcomes	 in	 this	 age-related	 disease.	 The	molecular	mecha-
nisms	by	which	ExT	induces	its	beneficial	effects	in	HFpEF,	however,	remain	largely	
unknown.	Given	the	strong	association	between	aging	and	HFpEF,	we	hypothesized	
that	ExT	might	reverse	cardiac	aging	phenotypes	that	contribute	to	HFpEF	patho-
physiology and additionally provide a platform for novel mechanistic and therapeutic 
discovery.	Here,	we	show	that	aged	(24–30	months)	C57BL/6	male	mice	recapitulate	
many	of	the	hallmark	features	of	HFpEF,	including	preserved	left	ventricular	ejection	
fraction,	subclinical	systolic	dysfunction,	diastolic	dysfunction,	impaired	cardiac	re-
serves,	exercise	intolerance,	and	pathologic	cardiac	hypertrophy.	Similar	to	older	hu-
mans,	ExT	in	old	mice	improved	exercise	capacity,	diastolic	function,	and	contractile	
reserves,	while	reducing	pulmonary	congestion.	Interestingly,	RNAseq	of	explanted	
hearts	showed	that	ExT	did	not	significantly	modulate	biological	pathways	targeted	
by	conventional	HF	medications.	However,	it	reversed	multiple	age-related	pathways,	
including	the	global	downregulation	of	cell	cycle	pathways	seen	in	aged	hearts,	which	
was	associated	with	 increased	capillary	density,	but	no	effects	on	cardiac	mass	or	
fibrosis.	Taken	together,	these	data	demonstrate	that	the	aged	C57BL/6	male	mouse	
is	a	valuable	model	for	studying	the	role	of	aging	biology	in	HFpEF	pathophysiology,	
and	provide	a	molecular	framework	for	how	ExT	potentially	reverses	cardiac	aging	
phenotypes	in	HFpEF.
K E Y W O R D S
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1  | INTRODUC TION
Heart	failure	with	preserved	ejection	fraction	(HFpEF)	is	a	complex,	
heterogenous clinical syndrome strongly associated with advanced 
age	 (Upadhya,	Taffet,	Cheng,	&	Kitzman,	2015).	 It	now	represents	
the	most	common	form	of	HF	in	older	adults	with	a	growing	prev-
alence	largely	attributed	to	global	population	aging	(Dunlay,	Roger,	
&	 Redfield,	 2017).	 Unfortunately,	 prognosis	 for	 older	 adults	 with	
HFpEF	remains	poor.	HF	remains	the	leading	cause	of	hospitalization	
amongst	persons	over	65	years	old,	and	nearly	1/3	of	all	older	adults	
hospitalized	 for	HF	 are	 either	 readmitted	 or	 dead	within	 90	 days	
of	 discharge	 (Upadhya	 et	 al.,	 2015).	 Notably,	 no	 pharmacological	
agent,	including	neurohormonal	antagonists	and	nitrate	derivatives	
(Borlaug	et	al.,	2018;	Massie	et	al.,	2008;	Pitt	et	al.,	2014;	Redfield	
et	al.,	2015),	has	 improved	survival	 in	HFpEF,	making	 it	one	of	the	
largest unmet needs in geriatric and cardiovascular medicine (Parikh 
et	al.,	2018).
The reasons we lack effective pharmacological interventions 
in	 HFpEF	 are	 multifold,	 but	 largely	 stem	 from	 an	 incomplete	
understanding	 of	 the	 underlying	 mechanisms	 that	 drive	 HFpEF	
pathophysiology	 (Roh,	 Houstis,	 &	 Rosenzweig,	 2017).	 In	 older	
adults,	molecular,	 structural,	 and	 functional	 changes	 associated	
with	cardiac	aging	have	long	been	hypothesized	to	be	major	con-
tributors	to	HFpEF	(Roh,	Rhee,	Chaudhari,	&	Rosenzweig,	2016;	
Strait	&	Lakatta,	2013;	Upadhya	et	al.,	2015).	However,	whether	
the	biology	of	cardiac	aging	can	be	 targeted	 for	HFpEF	 therapy	
is unclear.
Despite	limited	success	of	current	pharmacological	agents,	aer-
obic	exercise	training	(ExT)	has	emerged	as	one	of	the	most	effec-
tive strategies for improving functional outcomes in older adults 
with	HFpEF	 (Edelmann	et	al.,	2011;	Kitzman	et	al.,	2016;	Kitzman,	
Brubaker,	Morgan,	Stewart,	&	Little,	2010;	O’Connor	et	al.,	2009).	
Whether	 ExT	 can	 alter	 cardiac	 aging	 phenotypes	 that	 contribute	
to	HFpEF	 pathophysiology,	 however,	 is	 controversial.	While	 some	
studies	 have	 suggested	 that	 ExT	 improves	 diastolic	 function	 and	
cardiac	 reserves	 in	older	HFpEF	patients,	 others	have	 shown	 that	
ExT	has	minimal	effects	on	these	cardiac	aging	phenotypes	(Angadi	
et	al.,	2015;	Edelmann	et	al.,	2011;	Haykowsky	et	al.,	2012;	Kitzman	
et	al.,	2010,	2016;	Nolte	et	al.,	2014).	Moreover,	the	molecular	mech-
anisms	 by	which	 ExT	 potentially	 improves	 cardiac	 performance	 in	
HFpEF	are	unknown.
This study addresses these critical issues by first demonstrat-
ing	that	the	aged	C57BL/6	male	mouse	is	particularly	well	suited	
for	studying	the	role	of	aging	biology	in	HFpEF	pathophysiology.	
Using	this	age-related	HFpEF	model,	we	then	show	that	ExT	par-
tially	reverses	many,	but	not	all,	of	the	cardiac	aging	phenotypes	
associated	with	HFpEF.	Finally,	combining	RNAseq	profiling	and	
ExT	 in	 an	 integrated	 platform	 for	 therapeutic	 target	 discovery	
provides a scientific rationale for why previous drug targets may 
have	 failed	 in	clinical	HFpEF	 trials	and	 implicates	alternative	bi-
ological pathways as candidates for therapeutic intervention in 
age-related	HFpEF.
2  | RESULTS
2.1 | Cardiac functional HFpEF phenotyping
Since	 advanced	 age	 represents	 one	 of	 the	 dominant	 risk	 factors	
for	 HFpEF,	 we	 hypothesized	 that	 old	 mice	 might	 share	 hallmark	
phenotypes	present	 in	 human	HFpEF.	To	evaluate	 the	 aged	mouse	
as	a	HFpEF	model,	we	first	set	criteria	based	on	the	most	common	
pathophysiologic	 features	 seen	 in	 clinical	 HFpEF	 (Borlaug,	 2014;	
Mohammed	et	al.,	2015),	which	included	the	following:	(a)	preserved	
left	ventricular	 (LV)	systolic	function,	measured	by	ejection	fraction	
(EF)	or	 fractional	 shortening	 (FS);	 (b)	 impaired	exercise	 capacity;	 (c)	
impaired	contractile	or	chronotropic	reserves;	(d)	increased	intracar-
diac	 filling	 pressures,	 B-type	 natriuretic	 peptide	 (BNP)	 expression,	
or	pulmonary	congestion;	and	(e)	histologic	features	consistent	with	
pathologic	cardiac	hypertrophy.	Using	these	prespecified	criteria,	we	
performed	comprehensive	phenotyping	 in	 young	 (3–4	months),	 old	
(24–26	months),	 and	 very	 old	 (28–30	months)	C57BL/6	male	mice.	
Two	stages	of	advanced	age	were	used	to	determine	whether	HFpEF	
phenotypes progressed in the late stages of the murine lifespan to fur-
ther	investigate	the	role	of	aging	biology	in	HFpEF	pathophysiology.
Resting	cardiac	functional	phenotypes	were	assessed	using	an	ex-
tensive multimodality approach. Transthoracic echocardiography per-
formed in a large cohort of animals (n	=	43)	found	that	LV	fractional	
shortening	was	generally	preserved	in	old	and	very	old	mice,	compared	
to	young	mice	(Figure	1a).	Importantly,	this	defining	feature	of	HFpEF	
was further validated in smaller subgroups using cardiac magnetic res-
onance	 imaging	 (Figure	 S1)	 and	 invasive	 intracardiac	 hemodynamic	
testing	(Figure	S2).	Similar	to	human	HFpEF,	both	old	and	very	old	mice	
displayed	evidence	of	subclinical	LV	systolic	dysfunction	as	reflected	
in	reduced	systolic	strain	(Figure	1b).	Additionally,	impaired	myocardial	
relaxation,	a	marker	of	diastolic	dysfunction	commonly	seen	in	HFpEF,	
was	seen	in	aged	mice	(Figure	1c,	Figure	S2).
2.2 | Exercise HFpEF phenotyping
The	most	 consistent	 functional	 impairment	 seen	 in	 clinical	HFpEF	
is	 exercise	 intolerance	 (Borlaug,	 2014).	 Using	 stress	 echocardi-
ography,	 we	 found	 that	 exercise	 capacity	 was	 markedly	 reduced	
in	 old	 and	 very	 old	 mice,	 even	 when	 adjusted	 for	 body	 weight	
(Figure	2a,	Figure	S3).	Similar	to	human	aging	and	HFpEF	(Del	Buono	
et	al.,	2019;	Fleg	et	al.,	2005;	Strait	&	Lakatta,	2013),	there	was	an	
age-associated	decline	in	exercise	capacity	that	further	progressed	
from	24	to	30	months	 (Figure	2a).	Both	chronotropic	and	contrac-
tile	cardiac	reserves	decreased	with	age,	although	only	chronotropic	
reserves	 continued	 to	 decline	 from	 24	 to	 30	months	 (Figure	 2b).	
Both	chronotropic	and	contractile	reserves	correlated	with	exercise	
capacity	(Figure	2c),	suggesting	that	the	impairments	in	cardiac	re-
serves	seen	 in	older	mice	 likely	contribute	to	their	age-related	de-
cline	in	exercise	capacity.	Notably,	these	data	are	not	only	the	first	to	
demonstrate	a	marked	age-related	decrement	in	cardiac	reserves	in	
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C57BL/6	mice	in	the	context	of	exercise,	but	also	support	the	use	of	
this	model	for	studying	the	pathophysiology	of	age-related	HFpEF.
2.3 | Histopathologic cardiac HFpEF phenotyping
In	addition	to	the	cardiac	functional	impairments	and	exercise	intoler-
ance	seen	in	HFpEF,	postmortem	histopathologic	characterization	of	
hearts	from	HFpEF	patients	has	revealed	a	common	pathologic	car-
diac hypertrophy phenotype that includes increased cardiomyocyte 
size,	fibrosis,	and	microvascular	rarefaction	(Mohammed	et	al.,	2015).	
To	 determine	whether	 aged	C57BL/6	male	mice	 exhibit	 these	 his-
topathologic	 HFpEF	 phenotypes,	 we	 first	 performed	 gravimetric	
analyses	on	young,	old,	and	very	old	mice.	Indexed	lung	weights,	an	
indicator	 of	 pulmonary	 congestion,	 increased	with	 age	 (Figure	 S4),	
suggesting	 that	 as	 these	mice	 age,	 a	progressive	HF	 syndrome	oc-
curs	that	parallels	the	age-related	decline	 in	functional	exercise	ca-
pacity	(Figure	2).	Although	a	significant	increase	in	cardiac	mass	was	
seen	between	4	and	26	months,	there	was	no	further	increase	after	
26	months	(Figure	S4).	Thus,	we	focused	subsequent	analyses	on	the	
young and old age groups. Old mice fully recapitulated the patho-
logic	cardiac	hypertrophy	seen	 in	human	HFpEF,	demonstrating	 in-
creased	 cardiomyocyte	 size,	myocardial	 fibrosis,	 and	microvascular	
rarefaction	(Figure	3a),	which	was	associated	with	increased	cardiac	
BNP	expression,	a	biomarker	of	increased	myocardial	stress	and	HF	
(Figure	 3b).	 Notably,	 blood	 pressures	 were	 similar	 between	 young	
and	old	mice	 (Figure	3c),	suggesting	that	 the	pathologic	cardiac	re-
modeling seen in aged mice is not driven by overt hypertension but 
more likely related to processes intrinsic to cardiovascular aging.
2.4 | Reversal of HFpEF phenotypes in aged 
C57BL/6 male mice with exercise training
Since	 aged	 C57BL/6	male	mice	 recapitulate	many	 of	 the	HFpEF	
phenotypes	observed	in	older	humans,	we	next	examined	whether	
F I G U R E  1  Age-related	changes	in	resting	cardiac	function	in	C57BL/6	male	mice	are	similar	to	cardiac	functional	phenotypes	in	human	
HFpEF.	Nonsedated	transthoracic	echocardiography	in	C57BL/6	male	mice	at	3–4	months	(young	(Y),	n	=	12),	24–26	months	(old	(O),	n	=	17),	
and	28–30	months	(very	old	(VO),	n	=	14).	(a)	Fractional	shortening,	(b)	systolic	strain,	(c)	early	diastolic	strain	rate	(SR).	Data	shown	as	
mean ± SEM,	with	all	individual	data	points	plotted.	One-way	ANOVA	with	post	hoc	Tukey's	test	used	for	analyses.	*p	<	.05,	**p	<	.01,	***p < .001
F I G U R E  2  Progressive	age-related	decline	in	exercise	capacity	and	cardiac	reserves	in	C57BL/6	male	mice	recapitulates	exercise	
intolerance	phenotypes	in	human	HFpEF.	Stress	echocardiography	testing	in	C57BL/6	male	mice	at	3–4	months	(Y,	n	=	12),	24–26	months	
(O,	n	=	17),	and	28–30	months	(VO,	n	=	13).	(a)	Exercise	capacity	measured	by	total	distance	run	and	total	work	achieved	(adjusted	for	
body	weight).	(b)	Chronotropic	and	contractile	reserves	measured	at	peak	exercise.	(c)	Pearson	correlation	of	exercise	capacity	(work)	with	
chronotropic	or	contractile	reserves.	In	panels	a	and	b,	data	shown	as	mean	±	SEM,	with	all	individual	data	points	plotted,	and	one-way	
ANOVA	with	post	hoc	Tukey's	test	used	for	analyses.	*p	<	.05,	**p	<	.01,	***p < .001
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ExT	 could	 effectively	 reverse	 these	 age-related	 HFpEF	 phe-
notypes.	Mice	were	matched	 based	 on	 body	weight	 and	HFpEF	
phenotypes	 (Table	 1)	 and	 then	 divided	 into	 either	 an	 8-week	
moderate-intensity	 treadmill	 running	 protocol	 (45	 min	 at	 10	 m/
min	at	10°	 incline)	versus	no	 intervention	 (normal	sedentary	 life-
style)	 (Figure	4a).	ExT	 induced	multiple	functional	 improvements,	
some	of	which	have	been	reported	in	older	HFpEF	patients	(Angadi	
et	al.,	2015;	Edelmann	et	al.,	2011;	Haykowsky	et	al.,	2012;	Kitzman	
et	al.,	2010,	2016;	Nolte	et	al.,	2014).	Specifically,	 improvements	
in	exercise	capacity,	systolic	strain,	diastolic	function,	contractile	
reserves,	and	pulmonary	congestion	were	seen	after	eight	weeks	
of	ExT	(Figure	4b–e,	Figure	S5).	Although	cardiac	mass	and	fibro-
sis	were	not	significantly	changed,	capillary	density	increased	with	
ExT	(Figure	4f–h).
2.5 | Exercise-mediated transcriptome changes 
in the aged heart
To	explore	the	molecular	pathways	through	which	ExT	modulates	car-
diac	aging	phenotypes	associated	with	HFpEF,	we	performed	RNAseq	
on	a	subset	of	cardiac	samples	from	the	ExT	and	sedentary	aged	mice.	
Fourteen	genes	(11	of	which	are	known)	were	differentially	expressed	
after	 adjusting	 for	 multiple	 hypothesis	 testing	 (Figure	 5b,	 Table	 S1).	
Although	RNAseq	revealed	only	a	small	number	of	genes	 in	the	aged	
heart	 that	were	 differentially	 regulated	 by	 ExT,	 gene	 set	 enrichment	
analysis	 did	 identify	 479	 significantly	 upregulated	 and	77	 downregu-
lated	 biological	 pathways	 (Tables	 S2	 and	 S3).	 Interestingly,	 pathways	
associated	with	drug	targets	previously	tested	in	clinical	HFpEF	trials,	
that	 is,	 adrenergic,	 renin–angiotensin–aldosterone	 (RAAS)	 and	 nitric	
oxide-cGMP-phosphodiesterase	 signaling	 pathways,	 were	 generally	
not	 significantly	 altered	 by	 ExT,	 although	 positive	 regulation	 of	 nitric	
oxide	 synthase	 biosynthesis	 reached	 our	 significance	 threshold	 (NES	
1.67;	FDR	0.24)	and	cellular	responses	to	nitric	oxide	(NO)	had	a	positive	
trend	(NES	1.64,	FDR	0.26)	(Table	2).	Rather	the	pathways	most	highly	
upregulated	 by	 ExT	were	 predominantly	 cell	 cycle-related	 processes,	
while the most highly downregulated were related to cellular respiration 
(Tables	S2	and	S3).	Taken	together,	these	data	suggest	that	the	cardiac	
benefits	of	ExT	seen	in	older	animals	with	HFpEF	pathophysiology	may	
be	driven	more	by	changes	in	these	alternative	biological	pathways,	as	
opposed to the neurohormonal pathways that are targeted with current 
HF	medications.
F I G U R E  3   Pathologic cardiac 
hypertrophy	in	aged	C57BL/6	male	mice	
recapitulates histopathologic cardiac 
phenotypes	in	human	HFpEF.	(a)	Cardiac	
histopathologic	assessments	of	4-month	
(Y,	n	=	6–12)	and	25-	to	26-month	(O,	
n	=	6–9)	mice,	including	representative	
photomicrographs	and	quantification	of	
cardiomyocyte	cross-sectional	area	(CM	
CSA),	myocardial	fibrosis,	and	capillary	
density.	Scale	bar	=	100	µm.	(b)	Relative	
cardiac	mRNA	expression	of	BNP.	n = 5/
group.	(c)	Systemic	mean	arterial	pressure	
(MAP)	in	Y	(n	=	11)	versus	O	(n	=	8)	mice.	
For	all	panels,	data	shown	as	mean	±	SEM,	
with all individual data points plotted. 
Unpaired	Student's	t test used for 
analyses.	*p	<	.05,	**p	<	.01,	***p < .001
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2.6 | Reversal of cardiac aging pathways by 
exercise training
To	determine	whether	ExT	potentially	 reverses	 cardiac	 aging	biol-
ogy	associated	with	HFpEF,	we	next	assessed	how	the	cardiac	tran-
scriptome changes with normal aging to provide a comparison to the 
ExT-induced	transcriptome	seen	in	the	aged	heart.	Not	surprisingly,	
RNAseq	analyses	identified	a	large	number	of	genes	that	were	differ-
entially	expressed	in	30-month-old	compared	to	4-month-old	hearts	
(Figure	5a,	Table	S4).	Gene	set	enrichment	analysis	confirmed	that	
biological processes implicated in cardiac aging were changing in the 
expected	 directions	 in	 our	 aged	mice	 (Bergmann	 et	 al.,	 2009;	Dai	
et	al.,	2009;	Eisenberg	et	al.,	2016;	Hulsmans	et	al.,	2018;	Lee,	Alison,	
Brand,	Weindruch,	&	Prolla,	2002;	Roh	et	al.,	2016).	 Inflammation,	
cytokine	production,	complement	activation,	and	extracellular	ma-
trix	production	pathways	were	upregulated	in	the	aged	heart,	while	
cell	 cycle,	DNA	 repair,	mitochondrial	 function,	oxidative	phospho-
rylation,	fatty	acid	metabolism,	cardiac	contractility	and	relaxation,	
vasculogenesis,	autophagy,	and	proteasome	pathways	were	down-
regulated	 (Tables	 S5	 and	 S6).	Notably,	 the	 generalized	 increase	 in	
chronic inflammatory processes of the innate immune system along 
with downregulation of pathways relevant to cardiac muscle me-
chanics and vascular growth highlights the parallels between cardiac 
aging	biology	and	leading	HFpEF	hypotheses,	which	have	proposed	
a central role for microvascular inflammation inducing the cardio-
myocyte	dysfunction	seen	in	HFpEF	(Paulus	&	Tschope,	2013).
Comparative	analysis	between	the	aging	(4	mo	versus	30	mo)	and	
ExT	(30	mo	sedentary	vs.	30	mo	ExT)	cohorts	identified	216	path-
ways,	which	were	regulated	in	opposing	directions	by	aging	and	ExT	
(Tables	S2,	S3,	S5	and	S6).	Of	these	216	pathways,	the	most	highly	
significant changes predominantly occurred in cell cycle or cell di-
vision	pathways	 (Figure	5c),	suggesting	that	reversing	 impairments	
in	 this	 hallmark	 of	 aging	 (Lopez-Otin,	 Blasco,	 Partridge,	 Serrano,	
&	Kroemer,	 2013)	may	be	 an	 important	 contributor	 by	which	ExT	
improves the performance of the aged heart. The main drivers of 
the	three	most	highly	upregulated	pathways	(cell	cycle	process,	cell	
cycle,	mitotic	cell	cycle)	were	HAUS8, GADD45A, MAPRES2, MCM5, 
and FANCI.	 Increased	expression	 trends	of	 these	 genes	were	 vali-
dated by QPCR in an independent cohort of old male mice that 
underwent	 eight	 weeks	 of	 voluntary	 wheel	 running	 (Figure	 S6a),	
suggesting	that	different	modes	of	aerobic	ExT	can	induce	similar	bi-
ological	effects	in	the	aged	heart.	Although	the	changes	were	not	as	
robust	as	the	cell	cycle	changes	noted	above,	ExT	also	reversed	the	
downregulation	 of	 ubiquitin–proteasome,	 cellular	 stress	 response,	
heat	shock	protein	binding,	and	fatty	acid	metabolism	pathways	as-
sociated	with	aging	(Tables	S2,	S3,	S5	and	S6).
3  | DISCUSSION
HFpEF	is	a	clinical	syndrome	with	high	morbidity	and	mortality,	most	
commonly	seen	in	older	adults	(Dunlay	et	al.,	2017).	Given	the	lack	
of	effective	pharmacological	 therapies	 for	 this	disease,	 along	with	
its	projected	future	growth	with	ongoing	population	aging,	HFpEF	
has been labeled as one of the largest unmet needs in cardiovascular 
medicine	 (Parikh	et	al.,	2018).	The	reason	for	 the	 lack	of	effective	
therapies	in	HFpEF	is	multifold,	but	largely	due	to	an	incomplete	un-
derstanding	of	its	complex	pathophysiology.
This	study	addresses	one	of	the	major	shortcomings	in	this	field,	
which is the limited number of animal models to identify and study 
causal	molecular	mechanisms	in	HFpEF	(Roh	et	al.,	2017).	Previous	
studies	have	suggested	that	although	aged	mice	exhibit	some	fea-
tures	in	common	with	HFpEF,	they	do	not	necessarily	model	HFpEF	
(Dai	et	al.,	2009;	Eisenberg	et	al.,	2016).	The	mere	presence	of	car-
diac	HFpEF	phenotypes	in	mice	does	not	necessarily	equate	to	the	
clinical	syndrome	of	HF,	which	is	inherently	difficult	to	ascertain	in	
animals.	However,	 our	 comprehensive	 functional,	 histological,	 and	
molecular phenotyping provides strong evidence that the aged 
C57BL/6	male	mouse	 captures	many	of	 the	major	 cardiac	 pheno-
types that have been implicated as core pathophysiologic mediators 
of	HFpEF	(Borlaug,	2014).	Importantly,	the	HFpEF	phenotypes	ob-
served	 in	 aged	C57BL/6	male	mice	 occur	 in	 the	 absence	of	 overt	
hypertension,	 which	 has	 been	 a	 common	 adjunct	 intervention	
used	 to	 generate	HFpEF	 phenotypes	 in	 animal	models	 (Eisenberg	
et	al.,	2016;	Hulsmans	et	al.,	2018;	Schiattarella	et	al.,	2019).	Thus,	
we	propose	that	the	aged	C57BL/6	male	mouse	not	only	represents	
TA B L E  1  Baseline	characteristics	of	28-month-old	C57BL/6	
mice	included	in	the	exercise	training	substudy
Characteristic
Sedentary 
(n = 7)
Exercise 
(n = 7)
p 
value
Age	(month) 28 28 n.a.
Sex male male n.a.
Strain C57BL/6 C57BL/6 n.a.
Weight	(g) 31.6	±	2.9 34.8 ± 3.5 .09
Resting cardiac function
Fractional	
shortening	(%)
52.9 ± 3.2 50.2 ± 2.8 .12
Exercise	capacity
Distance	(m) 131.5	±	26.3 136.2	±	19.4 .71
Work	(Joules) 7.0	±	1.5 8.0	±	0.7 .16
Lactate	at	peak	
exercise	(mM)
8.2	±	1.6 9.0 ± 1.1 .28
Cardiac reserves
Chronotropic,	HR	
at	peak	exercise	
(bpm)
665.5	±	17.5 664.3	±	46.8 .95
Contractile,	Δ	FS	
at	peak	exercise	
(%)
0.2 ± 8.4 2.2 ± 5.0 .59
Note: Prior	to	initiation	of	the	exercise	training	protocol,	no	significant	
baseline	differences	in	body	weight,	resting	cardiac	function,	exercise	
capacity,	or	cardiac	reserves	were	detected	between	the	sedentary	
and	exercise-trained	groups.	n	=	7/group.	Data	shown	as	mean	±	SEM. 
Unpaired	Student's	t test used for analyses. p < .05 considered 
significant.
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a	valuable	and	complementary	model	of	HFpEF	but	 is	particularly	
well	suited	for	studying	the	role	of	aging	biology	 in	HFpEF	patho-
physiology.	This	supports	an	emerging	paradigm	in	this	field,	which	
suggests	that	given	the	heterogeneity	in	HFpEF,	effective	therapeu-
tic discovery and implementation will likely need to focus on specific 
subgroups	(e.g.,	older	adults)	in	which	the	primary	drivers	of	HFpEF	
may	differ	(Shah	et	al.,	2016).
The second major aim of this study was to begin to elucidate 
biological	mechanisms	by	which	ExT	potentially	alters	cardiac	aging	
phenotypes	that	contribute	to	HFpEF	in	older	adults.	Aerobic	ExT	
and caloric restriction have been the only interventions to improve 
functional	capacity	in	older	HFpEF	patients	in	randomized	clinical	
trials	(Kitzman	et	al.,	2016).	However,	due	to	limited	access	to	car-
diac	 tissue,	 the	 molecular	 mechanisms	 by	 which	 these	 interven-
tions	induce	these	benefits	have	remained	largely	unknown.	Here,	
we	 focused	specifically	on	ExT	with	 the	hypothesis	 that	 it	would	
induce	similar	functional	benefits	in	the	aged	C57BL/6	male	mouse	
and	 that	 RNAseq	 analyses	 of	 cardiac	 tissue	would	 not	 only	 pro-
vide	mechanistic	insights	into	the	role	of	ExT	in	cardiac	aging,	but	
also	potentially	identify	much-needed	novel	therapeutic	targets	for	
HFpEF.	Indeed,	our	findings	show	that	although	ExT	only	improves	
some	cardiac	HFpEF	phenotypes	in	this	model,	it	improves	overall	
cardiac	performance	 and	exercise	 capacity.	We	propose	 that	 the	
functional	parallels	seen	with	ExT	in	these	mice	and	humans	with	
HFpEF	 not	 only	 provide	 further	 support	 for	 the	 use	 of	 the	 aged	
C57BL/6	male	mouse	 as	 a	model	 of	 age-related	HFpEF,	 but	 also	
for	 the	use	of	ExT	as	a	platform	for	 therapeutic	discovery	 in	 this	
disease.
Importantly,	these	are	the	first	data	to	assess	how	ExT	modulates	
the	transcriptome	of	the	aged	heart	in	the	context	of	functional	phe-
notyping. Our analyses provide two major mechanistic insights into 
the	therapeutic	role	of	ExT	in	age-related	HFpEF.	First,	in	the	aged	
male	heart,	ExT	does	not	significantly	regulate	biological	pathways	
associated	 with	 conventional	 HF	 drugs,	 including	 β-blockers	 and	
RAAS	inhibitors.	This	is	consistent	with	the	failure	of	pharmacologi-
cal	therapies	targeting	these	pathways	to	improve	HFpEF	outcomes	
in	older	adults.	Borderline	significance	toward	enhanced	production	
or	cellular	responses	to	NO	was	detected	 in	our	pathway	analysis,	
which	could	suggest	that	NO	biology	may	still	be	a	promising	ther-
apeutic	 target	 for	 age-related	HFpEF.	 However,	 given	 the	 neutral	
results	 in	 randomized	controlled	 trials	with	organic	nitrate	and	 in-
organic	nitrite	therapies	(Borlaug	et	al.,	2018;	Redfield	et	al.,	2015),	
alternative	 approaches	 to	 targeting	 this	biology	need	 to	explored.	
Second,	 in	contrast	to	 its	 lack	of	effect	on	the	transcriptional	pro-
file	of	neurohormonal	pathways,	ExT	 induced	a	marked	reversal	 in	
the	global	downregulation	of	cell	cycle-related	pathways	seen	in	the	
aged	heart	 (Figure	 5c).	 This	 study	was	 not	 designed	 to	 determine	
which	cell	populations	this	signal	pertains	to.	However,	the	increase	
in	 capillary	 density	 and	upregulation	of	 angiogenesis	 pathways,	 in	
the	 absence	 of	 cardiac	mass	 or	 fibrosis	 changes,	 suggest	 that	 en-
dothelial	proliferation	is	 likely	involved,	which	would	be	consistent	
with	previous	reports	on	ExT-induced	cardiac	angiogenesis	(Lemitsu,	
F I G U R E  4  Aerobic	exercise	training	reverses	some	HFpEF	phenotypes	in	aged	male	mice.	(a)	Experimental	design	of	exercise	training	
substudy.	Prior	to	study	completion,	3	mice	died	in	the	sedentary	group	(SED)	and	2	mice	died	in	the	exercise-trained	group	(ExT).	(b)	Resting	
cardiac	function	by	strain	echocardiography.	(c)	Exercise	capacity.	(d)	Chronotropic	and	contractile	cardiac	reserves.	(e)	Lung	weight	(LW)	
normalized	to	tibial	length	(TL).	(f)	Heart	weight	(HW)	normalized	to	TL.	(g)	%	Fibrosis.	(h)	Capillary	density.	For	fibrosis	and	capillary	density	
measurements,	histologic	sections	from	a	SED	animal	that	died	one	day	prior	to	the	final	timepoint	functional	testing	were	included	in	
the final analyses. Data shown as mean ± SEM,	with	all	individual	data	points	plotted.	Unpaired	Student's	t	test	used	for	analyses.	*p	<	.05,	
**p	<	.01,	***p < .001
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Maeda,	Jesmin,	Otsuki,	&	Miyauchi,	2006)	and	the	trends	seen	in	NO	
pathways.	It	is	possible	that	ExT-induced	cardiomyogenesis	may	also	
be contributing to this signal. Recent work from our group has shown 
that	aerobic	ExT	generates	a	robust	increase	in	cardiomyogenesis	in	
young	mice	(Vujic	et	al.,	2018).	Although	this	has	yet	to	be	studied	in	
old	animals,	we	have	found	that	exercise-mediated	molecular	drivers	
of	cardiomyogenesis	not	only	modulate	proliferation	processes,	but	
often	promote	other	pro-survival	and	protective	growth	pathways	
in	cardiomyocytes	(Bostrom	et	al.,	2010;	Liu	et	al.,	2015).	Given	the	
profound cardiomyocyte loss and reduced regenerative capacity 
in	 the	aged	heart	 (Bergmann	et	 al.,	 2009),	 even	 small	 increases	 in	
cardiomyogenesis would likely have substantial impacts on cardiac 
function.
At	an	individual	gene	level,	after	adjusting	for	multiple	hypoth-
esis	 testing,	 our	 RNAseq	 analyses	 did	 identify	 11	 candidates	 that	
were	 differentially	 regulated	 by	 ExT	 in	 the	 aged	 heart	 (Figure	 5a,	
Table	S1).	Of	these	11	candidates,	the	increases	in	SORL1 and ACTA1 
expression	 were	 fully	 validated	 by	 QPCR	 in	 an	 independent	 ExT	
cohort	of	old	mice	(Figure	S6b).	SORL1	encodes	for	the	sortilin-like	
receptor	 1,	 a	 low-density	 lipid	 receptor,	 whose	 downregulation	
has	 been	 implicated	 in	 age-related	 Alzheimer	 disease	 (Rogaeva	
et	al.,	2007).	Although	SORL1	has	yet	to	be	studied	 in	the	context	
of	cardiac	aging,	HF,	or	exercise,	given	its	role	in	endosomal	protein	
recycling,	 it	 is	possible	 that	 its	upregulation	by	ExT	could	mitigate	
some	of	the	impaired	proteostasis	seen	in	cardiac	aging	and	HF.	The	
ExT-induced	upregulation	of	cardiac	ACTA1	expression	in	aged	mice	
was	unexpected.	ACTA1 is a member of the “fetal" gene profile typ-
ically increased in pathological cardiac hypertrophy and downregu-
lated	in	exercise-induced	physiological	hypertrophy	(Vega,	Konhilas,	
Kelly,	&	Leinwand,	2017).	However,	high-intensity	ExT	can	increase	
ACTA1	 expression	 in	 the	 heart	 (Castro	 et	 al.,	 2013).	 It	 is	 plausible	
that	even	though	our	ExT	protocol	was	initially	graded	as	moderate	
intensity,	it	became	progressively	more	strenuous	for	the	old	animals	
as	they	aged	over	8	weeks.	Although	we	did	not	detect	a	significant	
difference	in	cardiac	mass	in	our	ExT	old	mice,	average	cardiomyo-
cyte	 size	 increased	 by	 ~1.4-fold,	 which	 would	 be	 consistent	 with	
the increased cardiac ACTA1	expression	observed	with	ExT.	Further	
work	is	needed	to	determine	whether	exercise	intensity	has	differ-
ential effects on the “fetal gene” profile associated with pathologic 
cardiac	hypertrophy.	Importantly,	these	data	also	raise	the	question	
F I G U R E  5  Reversal	of	cardiac	aging	pathways	with	exercise	training.	RNAseq	analyses	on	cardiac	tissue	from	young	(4	months)	
sedentary,	very	old	(30	months)	sedentary,	and	very	old	(30	months)	exercise-trained	(ExT)	C57BL/6	male	mice.	ExT	mice	completed	an	
8-week	treadmill	running	protocol	from	28	to	30	months	prior	to	sacrifice.	n	=	3/group.	(a)	Volcano	plot	of	differentially	expressed	genes	
between	young	and	very	old	sedentary	mice.	(b)	Volcano	plot	of	differentially	expressed	genes	between	sedentary	and	ExT	very	old	mice.	(c)	
Most	highly	significant	pathways	that	are	differentially	regulated	in	opposing	directions	by	age	(red,	young	sedentary	vs.	very	old	sedentary)	
and	ExT	(blue,	very	old	sedentary	vs.	very	old	ExT).	Only	pathways	with	an	FDR	<	0.05	in	both	the	aging	and	exercise-trained	cohorts	with	
normalized	enrichment	scores	(NES)	in	opposing	directions	are	displayed.	For	volcano	plots,	black	=	nonsignificant;	orange	=	log2(FC)	≥1;	
red = padj < .05; green = log2(FC)	≥1	+	padj < .05
8 of 12  |     ROH et al.
of	whether	the	fetal	gene	expression	profile	can	reliably	distinguish	
between physiologic and pathologic hypertrophy in older animals 
and humans. Evidence in humans has suggested that moderate in-
tensity	distance	 running	 specifically	 increases	circulating	BNP,	an-
other member of the pathologic cardiac hypertrophy fetal gene 
profile,	 in	older,	but	not	younger	humans	 (Kim	et	al.,	2017).	 In	our	
ExT	old	mice,	the	improvements	in	cardiac	function	and	absence	of	
fibrotic changes suggest that despite an overall upregulation in the 
fetal	gene	expression	profile,	exercise	appears	 to	 induce	a	benefi-
cial	effect	 in	 the	aged	murine	heart.	Lastly,	 it	 is	 important	 to	note	
that	our	RNAseq	analyses	did	not	identify	significant	transcriptional	
changes	in	targets	that	have	been	previously	reported	in	ExT	aged	
rodents,	such	as	SERCA2a,	VEGF,	and	SIRT1	(Lai	et	al.,	2014;	Lemitsu	
et	al.,	2006;	Tate	et	al.,	1996).	However,	it	is	likely	that	some	of	these	
TA B L E  2  Effects	of	exercise	training	in	aged	hearts	on	biological	pathways	associated	with	previously	tested	drug	targets	in	HFpEF
Pathway NES FDR
Adrenergic system
Adrenergic	receptor	activity 0.89 0.81
Adrenergic	receptor	binding 0.69 0.94
Adrenergic	receptor	signaling	pathway 0.88 0.82
Catecholamine binding 1.01 0.73
Catecholamine biosynthetic process 0.95 0.76
Catecholamine metabolic process 1.33 0.49
Catecholamine transport 1.18 0.60
Negative	regulation	of	catecholamine	secretion 1.01 0.73
Positive regulation of catecholamine metabolic process −1.13 0.82
Regulation of norepinephrine secretion −1.00 0.88
Response to epinephrine −1.38 0.71
Renin–angiotensin–aldosterone system
Angiotensin	receptor	binding −0.85 0.93
Regulation	of	blood	volume	by	renin–angiotensin 0.98 0.75
Regulation	of	systemic	arterial	blood	pressure	by	circulating	renin–angiotensin 1.48 0.38
Regulation	of	systemic	arterial	blood	pressure	by	renin–angiotensin 1.45 0.40
Response to mineralocorticoid −0.86 0.93
Nitric oxide-cGMP-phosphodiesterase system
3’5’	cGMP	phosphodiesterase	activity −1.56 0.57
Cellular	response	to	nitric	oxide 1.64 0.26
cGMP binding −1.13 0.82
cGMP biosynthetic process 1.10 0.66
cGMP metabolic process 1.08 0.68
Negative	regulation	of	nitric	oxide	metabolic	process 0.95 0.76
Nitric	oxide	mediated	signal	transduction −1.45 0.67
Nitric	oxide	metabolic	process 1.29 0.52
Nitric	oxide	synthase	binding −1.08 0.84
Positive	regulation	of	nitric	oxide	synthase	activity −0.96 0.90
Positive	regulation	of	nitric	oxide	synthase	biosynthetic	process 1.67 0.24
Regulation of cGMP biosynthetic process −1.03 0.86
Regulation of cGMP metabolic process 1.08 0.68
Regulation	of	nitric	oxide	biosynthetic	process −0.86 0.93
Regulation	of	nitric	oxide	synthase	activity −0.77 0.97
Regulation	of	nitric	oxide	synthase	biosynthetic	process 1.42 0.42
Response	to	nitric	oxide 1.50 0.36
Note: Gene	set	enrichment	analysis	of	RNAseq	profiles	from	cardiac	tissue	of	sedentary	versus	exercise-trained	aged	male	mice	using	the	Gene	
Ontology pathway dataset. N	=	3/group.	NES	=	normalized	enrichment	score.	False	discovery	rate	(FDR)	<0.25	considered	significant.
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targets,	such	as	SERCA2a,	are	largely	regulated	at	a	post-transcrip-
tional	level	in	the	aged	heart	(Roh	et	al.,	2019).
Some	 limitations	 of	 the	 study	 warrant	 emphasis.	 First,	 this	
study	was	 done	 exclusively	 in	male	mice	 and,	 thus,	 does	 not	 ad-
dress	sex-related	differences	 in	age-related	HFpEF.	Evidence	sug-
gests that there are likely molecular differences in how male and 
female	hearts	age,	and	moreover,	how	they	remodel	in	response	to	
physiologic	and	pathologic	stress	(Konhilas	et	al.,	2004;	Piro,	Della	
Bona,	Abbate,	Biasucci,	&	Crea,	2010;	Weinberg	et	al.,	1999).	While	
our	 findings	strongly	suggest	 that	 the	aged	C57BL/6	male	mouse	
recapitulates	many	of	the	clinical	HFpEF	phenotypes,	further	work	
needs	to	be	done	to	determine	whether	HFpEF	phenotypes	are	also	
present	in	aged	female	mice,	and	if	cell	cycle	pathways	are	similarly	
modulated	by	age	and	exercise	in	females.	Second,	although	we	in-
cluded	many	of	 the	 core	 pathophysiologic	 features	 in	 our	HFpEF	
phenotyping,	 this	did	not	 include	assessment	of	other	potentially	
causal	 comorbidities,	 such	 as	 obesity,	 or	 the	 role	 of	 peripheral	
mechanisms	 in	 HFpEF	 pathophysiology	 (Borlaug,	 2014;	 Kitzman	
et	al.,	2016).	Noncardiac	phenotypes	likely	contribute	to	the	age-re-
lated	exercise	intolerance	seen	in	this	model	and	need	to	be	further	
investigated.	Third,	while	no	differences	 in	systemic	arterial	pres-
sure	were	detected	between	young	and	old	mice,	we	did	not	assess	
for	changes	in	aortic	stiffness,	which	increases	with	age	and	could	
also be contributing to the pathologic cardiac hypertrophy pheno-
type	seen	 in	 this	aged	mouse	model	 (Fleenor	et	al.,	2014).	Lastly,	
altered	pathways	were	identified	using	RNAseq	on	whole	heart	ex-
tracts.	Thus,	while	this	is	the	first	ExT-related	transcriptome	analy-
ses	in	aged	hearts,	future	studies	will	need	to	define	the	specific	cell	
populations driving the functional and molecular changes induced 
by	ExT	in	the	aged	heart.	Moreover,	RNAseq	does	not	identify	reg-
ulation	that	occurs	at	the	level	of	protein	expression	or	post-trans-
lational modifications of protein.
Taken	 together,	 this	 study	addresses	 some	of	 the	major	 short-
comings	 in	 HFpEF	 research,	 particularly	 in	 the	 context	 of	 aging.	
It	 establishes	 the	 aged	C57BL/6	male	mouse	 as	 a	 valuable	model	
for	 studying	 the	 role	 of	 aging	 biology	 in	 HFpEF	 pathophysiology.	
Moreover,	by	using	ExT	as	a	platform	 for	 therapeutic	discovery,	 it	
identifies	multiple	pathways	implicated	in	cardiac	aging,	most	nota-
bly	impaired	cell	cycle-related	pathways,	that	may	potentially	repre-
sent	promising	 targets	 for	 therapeutic	development	 in	age-related	
HFpEF.
4  | E XPERIMENTAL PROCEDURES
4.1 | Mice
All	 animal	 studies	 were	 approved	 by	 the	 Beth	 Israel	 Deaconess	
Medical Center and Massachusetts General Hospital Institutional 
Animal	Care	and	Use	Committees.	Aged	C57BL/6	males	were	gen-
erously	provided	by	the	National	Institute	on	Aging.	Aged	C57BL/6	
females	were	unavailable	at	the	time	of	this	study.	Young	C57BL/6	
males	were	purchased	from	Jackson	Laboratory.
4.2 | Echocardiography
Echocardiography	 was	 performed	 on	 unanesthetized	 mice	 with	
Vivid	7	and	E90	systems	(GE	Healthcare).	Systolic	function	was	as-
sessed	by	 fractional	 shortening	and	radial	 systolic	strain,	while	di-
astolic function was assessed by early diastolic strain rate. Refer to 
supplemental methods for details on echocardiographic image ac-
quisition	and	analysis.
4.3 | Cardiac magnetic resonance imaging
Mice	were	 anesthetized	with	 isoflurane	 and	 imaged	 using	 a	 9.8-T	
MRI	system	(Bruker	Biospin).	Refer	to	supplemental	methods	for	de-
tails of the cardiac MRI protocol.
4.4 | Invasive intracardiac hemodynamics
Mice	were	 anesthetized	with	 isoflurane	 and	mechanically	 venti-
lated	throughout	the	procedure.	The	LV	was	entered	via	the	right	
carotid	artery	with	a	Scisence	1.2F	high-fidelity	micromanometer	
catheter	(Transonic	Systems	Inc.)	to	record	pressure-volume	(PV)	
loops.	PV	loops	were	analyzed	off-line	with	LabScribe2	software	
(iWorx).
4.5 | Stress echocardiography exercise testing
To	measure	exercise	capacity	and	cardiac	 reserves,	 a	 stress	echo-
cardiography	protocol	was	designed	in	which	mice	were	run	to	ex-
haustion and then immediately imaged via echocardiography. Refer 
to the supplemental methods for details of the protocol.
4.6 | Exercise training protocols
Two	aerobic	exercise	training	protocols	were	used	in	this	study.	 In	
the	 initial	 discovery	 cohort,	 moderate-intensity	 treadmill	 running	
was performed five days per week for eight consecutive weeks. 
Treadmill running was done on an automated treadmill (Columbus 
Instruments)	 at	 a	 constant	 speed	 of	 10	 m/min	 at	 10°	 incline.	 To	
ensure	that	the	biological	effects	of	ExT	were	not	limited	to	a	spe-
cific	type	of	aerobic	exercise,	we	also	performed	eight	consecutive	
weeks	of	 voluntary	wheel	 running	 (STARR	Life	 Sciences)	 in	 an	 in-
dependent	 validation	 cohort,	 using	 previously	 published	 methods	
(Vujic	et	al.,	2018).
4.7 | Histologic and immunohistochemical analyses
Formalin-fixed,	 paraffin-embedded	 mid-ventricular	 sections	 were	
stained	with	 periodic	 acid–Schiff	 for	 cardiomyocyte	 cross-sectional	
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area	 (CSA),	 Masson's	 trichrome	 for	 fibrosis,	 and	 rabbit-anti-mouse	
CD31	(1:50,	Cell	Signaling	Technologies,	#77699)	for	capillary	density.	
Cardiomyocyte	CSAs	were	measured	in	three	to	five	random	sections	
(40–60	cells/section,	~200	cells/heart),	which	were	averaged	to	rep-
resent	a	single	data	point	for	each	heart.	Capillary	density	was	quanti-
fied	by	dividing	the	number	of	CD31+	cells	by	the	area	of	randomly	
selected sections. Three to five sections were measured per heart and 
averaged	to	represent	a	single	data	point.	Given	the	extensive	variabil-
ity	 in	fibrosis	distribution	throughout	the	heart,	BZ-X	Analyzer	soft-
ware	 (Keyence)	was	used	 to	quantify	 fibrosis	 in	 full	mid-ventricular	
sections. Percent fibrosis was calculated as the ratio of fibrotic area 
to total tissue area. Measurements from two sections were averaged 
to represent a single data point for each heart. Quantitative histologic 
analyses were done in a blinded fashion.
4.8 | Quantitative real-time PCR
Real-time	PCR	products	were	 carried	out	using	SYBR-green	and	
standard	 amplification	 protocols.	 Expression	 levels	 were	 cal-
culated using the ΔΔCt	 method.	 Primer	 sequences	 are	 listed	 in	
Table	S7.
4.9 | RNA sequencing
RNA	 sequencing	 was	 performed	 by	 the	 MGH	 Sequencing	 Core.	
Libraries	were	constructed	from	polyA-selected	RNA	using	a	NEBNext	
Ultra	Directional	RNA	Library	Prep	Kit	(New	England	Biolabs)	and	se-
quenced	on	 Illumina	HiSeq2500	 instrument.	The	R	package	DESeq2	
was	used	 for	 differential	 gene	expression	 analysis.	Genes	were	 con-
sidered	 differentially	 expressed	 if	 upregulated	 by	 log2FC>+1	 or	
downregulated by log2FC<−1	 with	 an	 adjusted	 p value < .05 (using 
Benjamini-Hochberg	correction).	Pathway	analysis	was	performed	with	
Gene	Set	Enrichment	Analysis	(GSEA,	Broad	Institute)	using	the	Gene	
Ontology	 database.	 For	 all	 differentially	 expressed	 genes,	 a	 metric	
was	computed	as	the	product	of	logFC	and	−log10(p-value).	A	“running	
sum” statistic was calculated for each gene set in the pathway data-
base based on the ranks of the members of the set relative to those of 
the	nonmembers.	Enrichment	score	(ES)	was	defined	as	the	maximum	
sum	of	the	running	sum	with	the	genes	making	up	this	maximum	ES	
contributing	to	the	core	enrichment	in	that	pathway.	A	normalized	en-
richment	score	(NES)	was	generated	based	on	the	gene	set	enrichment	
scores for all dataset permutations. Pathways with a false discovery 
rate	(FDR)	<0.25	were	considered	significant.
4.10 | Statistical analyses
RNAseq	 and	 GSEA	 data	 analyses	 were	 performed	 with	 R	 and	
DESeq2	software,	as	described	in	Section	4.9.	GraphPad	Prism	(ver-
sion	7.0)	was	used	for	all	other	data	analyses.	In	all	graphs,	data	are	
shown as means ± SEM	with	all	individual	data	points	displayed.	For	
comparisons	 of	 two	 groups,	 unpaired	 Student's	 t tests were per-
formed.	For	comparisons	of	≥3	groups,	one-way	ANOVA	followed	
by	post	hoc	Tukey's	multiple	comparison	testing	was	done.	Pearson	
method	was	used	for	correlation	studies	in	Figure	2.	p value <.05 was 
considered statistically significant.
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